Paradigm Biopharmaceuticals Limited (PAR.AX) — Stock Score Summary

Paradigm Biopharmaceuticals Limited (PAR.AX) has a MoatMap StockRank of 0/100 based on Quality (10/100), Value (28/100), and Momentum (16/100) factor scores. The current signal is STRONG SELL. Paradigm Biopharmaceuticals is a clinical-stage biotech company. It lacks commercial revenues, has high cash burn, and does not align with our high-conviction CDMO pricing power theme, which focuses on established manufacturing gatekeepers rather than speculative drug developers.

Paradigm Biopharmaceuticals Limited is a late-stage clinical biopharmaceutical company focused on repurposing pentosan polysulfate sodium (PPS) to treat inflammatory diseases, primarily osteoarthritis. The company's lead candidate, Zilosul, targets a massive global market with limited disease-modifying treatment options. Paradigm's competitive position is secured by extensive patent protection, proprietary clinical data, and an advanced Phase 3 clinical trial program.

Key Financial Metrics

Price$0.10
Market Cap$62M
P/E (Forward)-1.45
Price/Book10.36
Return on Equity-180.2%
Debt/Equity156.37
Gross Margin24.5%
Operating Margin-86793.9%
Revenue Growth50.6%
Free Cash Flow$-9M

Paradigm Biopharmaceuticals Limited operates in the Biotechnology industry, part of the Healthcare sector (Australia).

Frequently Asked Questions

What is Paradigm Biopharmaceuticals Limited’s (PAR.AX) StockRank?
MoatMap’s StockRank for Paradigm Biopharmaceuticals Limited (PAR.AX) is 0/100, with a Strong Sell signal. It is a composite of Quality (10), Value (28), and Momentum (16) factor ranks across MoatMap’s 19,000+ stock universe.
Does Paradigm Biopharmaceuticals Limited have an economic moat?
Paradigm Biopharmaceuticals Limited (PAR.AX) has a Quality factor score of 10/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Paradigm Biopharmaceuticals Limited a buy, hold, or sell?
MoatMap’s current signal for Paradigm Biopharmaceuticals Limited (PAR.AX) is Strong Sell, based on a StockRank of 0/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Paradigm Biopharmaceuticals Limited in?
Paradigm Biopharmaceuticals Limited (PAR.AX) operates in the Healthcare sector, specifically the Biotechnology industry (Australia).
Browse all ranked stocksPAR.AX deep dive reportAI ChampionsHow we score stocksSense-check another stock